PGxPopulation

Rather than testing everyone, PGxPopulation enables laboratories, independent software vendors, and healthcare providers to save time and money by looking at a cohort and seeing which populations should participate in pharmacogenomics testing.

For population health programs, knowing how to allocate resources and when to screen patients can increase the quality of care and services delivered. Translational Software’s PGxPopulation identifies the gene-specific reasons that a pharmacogenomics test may be beneficial, helping reduce the risk of adverse events and lowering healthcare costs.

Preventative screening programs are more effective when providers are focused on patients who need PGx testing the most. Some  relevant populations include:

• Long-term care patients: Evaluate your patient population periodically to ensure they’re receiving the appropriate clinical therapy to reduce adverse drug reactions.
• Transitional care patients: Properly review gene-medication interactions to prevent readmissions for older adults when entering post-acute care.
• Employee benefits: Improve metrics around absenteeism and increase overall productivity by ensuring the appropriateness of medication therapies for your workforce.